Positive results for dual GLP-1/GIP receptor agonist in obesity


Viking Therapeutics has reported positive top-line results from the Phase II VENTURE trial of VK2735 in patients with obesity.

VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

The study demonstrated statistically significant reductions in body weight at all doses as compared to placebo, up to 13.1% placebo-adjusted mean weight loss.

The company has seen a 134% increase in its share price following the announcement.

In the trial, patients receiving weekly doses of VK2735 demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 14.7% from baseline.

Reductions in body weight were progressive through the course of the study, with no plateau observed for weight loss at 13 weeks. Up to 88% of patients in VK2735 treatment groups achieved ≥10% weight loss, compared with 4% for placebo.

VK2735 demonstrated encouraging safety and tolerability following 13 weeks of once-weekly dosing. Among patients receiving VK2735, the majority (92%) reported drug related TEAEs as mild or moderate in severity.

Further weight loss could be achieved

Brian Lian, Chief Executive Officer of Viking, said: “No evidence of a plateau was observed at Week 13 for any VK2735 dose, suggesting further weight loss might be achieved from extended dosing periods. We look forward to progressing this important therapy into further clinical development later this year. Separately, we remain on track to report data from a Phase I study of an oral formulation of VK2735 later this quarter.”

Activation of the GLP-1 receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Recent research efforts have explored the potential co-activation of the GIP receptor to enhance the therapeutic benefits. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the US Food and Drug Administration.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free